Q32 Bio Inc
QTTB
NASDAQ
Biotechnology
$15.15
USD
-0.22 (-1.43%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $468.57M
Volume 311.8K
Revenue
$53.74M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$33.79M
TTM
+164.6%
YoY
Operating Cash Flow
$-19.83M
TTM
+63.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 53.7 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 53.7 | 0.0 | 0.0 |
Selling, General & Administrative | 4.0 | 4.0 | 4.5 | 4.5 | 4.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.2 | 7.6 | 7.9 | 7.7 | 9.1 |
Operating Income | -9.2 | -7.6 | 45.9 | -7.7 | -9.1 |
EBITDA | -9.1 | -7.5 | 46.0 | -7.6 | -9.0 |
Other Income / Expense | -0.3 | 0.2 | 11.9 | 0.1 | 0.2 |
Total Other Income / Expense | -0.3 | 0.2 | 11.9 | 0.1 | 0.2 |
Income Before Income Taxes | -9.5 | -7.4 | 57.7 | -7.6 | -8.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.5 | -7.4 | 57.7 | -7.6 | -8.9 |
Consolidated Net Income / Loss | -9.5 | -7.4 | 57.7 | -7.6 | -8.9 |
Net Income Attributable to Common Shareholders | -9.5 | -7.4 | 57.7 | -7.6 | -8.9 |
Basic EPS | -$0.78 | -$0.60 | $4.59 | -$0.54 | -$0.44 |
Diluted EPS | -$0.78 | -$0.60 | $4.57 | -$0.54 | -$0.44 |
Basic Shares Outstanding | 12.2M | 12.2M | 12.6M | 14.1M | 20.3M |
Diluted Shares Outstanding | 12.2M | 12.2M | 12.6M | 14.1M | 20.3M |